184 related articles for article (PubMed ID: 29040895)
1. Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey.
Ökem ZG; Örgül G; Kasnakoglu BT; Çakar M; Beksaç MS
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():40-44. PubMed ID: 29040895
[TBL] [Abstract][Full Text] [Related]
2. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program.
Ayres AC; Whitty JA; Ellwood DA
Aust N Z J Obstet Gynaecol; 2014 Oct; 54(5):412-7. PubMed ID: 25196262
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free DNA-Based Non-invasive Prenatal Screening for Common Aneuploidies in a Canadian Province: A Cost-Effectiveness Analysis.
Nshimyumukiza L; Beaumont JA; Duplantie J; Langlois S; Little J; Audibert F; McCabe C; Gekas J; Giguère Y; Gagné C; Reinharz D; Rousseau F
J Obstet Gynaecol Can; 2018 Jan; 40(1):48-60. PubMed ID: 28784564
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.
Song K; Musci TJ; Caughey AB
J Matern Fetal Neonatal Med; 2013 Aug; 26(12):1180-5. PubMed ID: 23356557
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.
Zhang W; Mohammadi T; Sou J; Anis AH
PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591
[TBL] [Abstract][Full Text] [Related]
7. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.
O'Leary P; Maxwell S; Murch A; Hendrie D
Aust N Z J Obstet Gynaecol; 2013 Oct; 53(5):425-33. PubMed ID: 24090461
[TBL] [Abstract][Full Text] [Related]
8. Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis.
Shang W; Wan Y; Chen J; Du Y; Huang J
BMJ Open; 2021 Jul; 11(7):e046582. PubMed ID: 34230019
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
Dhaifalah I; Májek O
Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
[TBL] [Abstract][Full Text] [Related]
10. Health economic evaluation of noninvasive prenatal testing and serum screening for down syndrome.
Xiao G; Zhao Y; Huang W; Hu L; Wang G; Luo H
PLoS One; 2022; 17(4):e0266718. PubMed ID: 35421148
[TBL] [Abstract][Full Text] [Related]
11. The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis.
Bayón JC; Orruño E; Portillo MI; Asua J
Cost Eff Resour Alloc; 2019; 17():6. PubMed ID: 30867656
[TBL] [Abstract][Full Text] [Related]
12. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
Ohno M; Caughey A
Prenat Diagn; 2013 Jul; 33(7):630-5. PubMed ID: 23674316
[TBL] [Abstract][Full Text] [Related]
13. A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21.
Wang S; Liu K; Yang H; Ma J
Front Public Health; 2022; 10():870543. PubMed ID: 35712262
[TBL] [Abstract][Full Text] [Related]
14. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.
Chitty LS; Wright D; Hill M; Verhoef TI; Daley R; Lewis C; Mason S; McKay F; Jenkins L; Howarth A; Cameron L; McEwan A; Fisher J; Kroese M; Morris S
BMJ; 2016 Jul; 354():i3426. PubMed ID: 27378786
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.
García-Pérez L; Linertová R; Álvarez-de-la-Rosa M; Bayón JC; Imaz-Iglesia I; Ferrer-Rodríguez J; Serrano-Aguilar P
Eur J Health Econ; 2018 Sep; 19(7):979-991. PubMed ID: 29249015
[TBL] [Abstract][Full Text] [Related]
16. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
17. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.
Morris S; Karlsen S; Chung N; Hill M; Chitty LS
PLoS One; 2014; 9(4):e93559. PubMed ID: 24714162
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China.
Xu Y; Wei Y; Ming J; Li N; Xu N; Pong RW; Chen Y
Int J Technol Assess Health Care; 2019 Jan; 35(3):237-242. PubMed ID: 31131776
[TBL] [Abstract][Full Text] [Related]
19. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
[TBL] [Abstract][Full Text] [Related]
20. Women's preference for non-invasive prenatal DNA testing versus chromosomal microarray after screening for Down syndrome: a prospective study.
Cheng Y; Leung WC; Leung TY; Choy KW; Chiu R; Lo TK; Kwok KY; Sahota DS
BJOG; 2018 Mar; 125(4):451-459. PubMed ID: 29125674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
